<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Inst Med Trop Sao Paulo</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rev. Inst. Med. Trop. Sao Paulo</journal-id>
      <journal-title-group>
        <journal-title>Revista do Instituto de Medicina Tropical de S&#xE3;o Paulo</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0036-4665</issn>
      <issn pub-type="epub">1678-9946</issn>
      <publisher>
        <publisher-name>Instituto de Medicina Tropical</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25229227</article-id>
      <article-id pub-id-type="pmc">4172118</article-id>
      <article-id pub-id-type="publisher-id">S0036-46652014000500013</article-id>
      <article-id pub-id-type="doi">10.1590/S0036-46652014000500013</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>INTERFERON BETA-1A TREATMENT IN HTLV-1-ASSOCIATED
MYELOPATHY/TROPICAL SPASTIC PARAPARESIS: A CASE REPORT</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Tratamento com interferon beta-1a em mielopatia associada ao
HTLV-1/paraparesia esp&#xE1;stica tropical: relato de
caso</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Viana</surname>
            <given-names>Gra&#xE7;a Maria de Castro</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>da Silva</surname>
            <given-names>Marcos Antonio Cust&#xF3;dio Neto</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>(2)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Souza</surname>
            <given-names>Victor Lima</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>(2)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lopes</surname>
            <given-names>Nat&#xE1;lia Barbosa da Silva</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>(2)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>da Silva</surname>
            <given-names>Diego Luz Felipe</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>(2)</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nascimento</surname>
            <given-names>Maria do Desterro Soares Brand&#xE3;o</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>(1)</sup>
</xref>
        </contrib>
        <aff id="aff1"><label>(1)</label>
Departamento de Patologia, Universidade Federal do
Maranh&#xE3;o, S&#xE3;o Luis, MA, Brazil, Departamento de Patologia, Universidade
Federal do Maranh&#xE3;o, S&#xE3;o Luis, MA, Brazil. E-mails: gracaviana@globo.comcnsd_ma@uol.com.br</aff>
        <aff id="aff2"><label>(2)</label>
Curso de Medicina, Universidade Federal do
Maranh&#xE3;o, S&#xE3;o Luis, MA, Brazil, Curso de Medicina, Universidade Federal do
Maranh&#xE3;o, S&#xE3;o Luis, MA, Brazil. E-mails: marcos_antonio456@hotmail.comvictorlima_s@yahoo.com.brnatalia@hotmail.comdiego@hotmail.com</aff>
      </contrib-group>
      <author-notes>
        <corresp><bold>Correspondence to:</bold> Gra&#xE7;a Maria de Castro Viana,
Pra&#xE7;a Madre Deus 1, Madre Deus, S&#xE3;o Luis, MA, Brasil. E&#x2013;mail:
<email>gracaviana@globo.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2014</year>
      </pub-date>
      <volume>56</volume>
      <issue>5</issue>
      <fpage>443</fpage>
      <lpage>445</lpage>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>2</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License, which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p id="para1">Here a young patient (&lt; 21 years of age) with a history
of infective dermatitis is described. The patient was diagnosed with myelopathy
associated with HTLV-1/tropical spastic paraparesis and treated with
interferon beta-1a. The disease was clinically established as HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP), and
laboratory tests confirmed the presence of antibodies to HTLV-1 in the
cerebrospinal fluid (CSF). Mumps, cytomegalovirus, Epstein-Barr virus,
schistosomiasis, herpes virus 1 and 2, rubella, measles, varicella-zoster
toxoplasmosis, hepatitis, HIV, and syphilis were excluded by serology. The
patient was diagnosed with neurogenic bladder and presented with nocturia,
urinary urgency, paresthesia of the lower left limb, a marked reduction of
muscle strength in the lower limbs, and a slight reduction in upper limb
strength. During the fourth week of treatment with interferon beta-1a, urinary
urgency and paresthesia disappeared and clinical motor skills improved.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p id="para2">Descreve-se caso de mielopatia associada ao HTLV-1/paraparesia
esp&#xE1;stica tropical tratada com interferon beta-1a em paciente jovem de 21
anos e com hist&#xF3;ria de dermatite infecciosa na inf&#xE2;ncia. Foi
estabelecida clinicamente paraparesia esp&#xE1;stica tropical
(HAM/TSP), confirmada laboratorialmente pela presen&#xE7;a de
anticorpos para HTLV-1 no LCR e exclu&#xED;das caxumba, citomegalovirus,
Epstein-Barr, esquistossomose, herpes virus 1 e 2, rub&#xE9;ola, sarampo,
toxoplasmose varicela-zoster, hepatite, HIV e s&#xED;filis por sorologias. Foi
diagnosticada bexiga neurog&#xEA;nica, com quadro cl&#xED;nico de nict&#xFA;ria,
urg&#xEA;ncia urin&#xE1;ria, parestesia no membro inferior esquerdo e discreta
redu&#xE7;&#xE3;o de for&#xE7;a muscular nos membros superiores, mais acentuada
nos membros inferiores. Na 4<sup>a</sup> semana de tratamento com interferon
beta-1a houve desaparecimento da urg&#xEA;ncia urin&#xE1;ria e da parestesia e
melhora da cl&#xED;nica motora.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>HAM/TSP</kwd>
        <kwd>HTLV-1</kwd>
        <kwd>Interferon beta-1a</kwd>
        <kwd>Treatment</kwd>
      </kwd-group>
      <counts>
        <fig-count count="0"/>
        <table-count count="0"/>
        <ref-count count="16"/>
        <page-count count="3"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p id="para3">The human T-lymphotropic virus (HTLV) is a retrovirus belonging
to the Retroviridae family. HTLV can infect cells of the human immune system and has
tropism for T-lymphocytes<sup><xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref></sup> (T-cells). Approximately
10-20 million people worldwide are infected with HTLV-1, which is considered a
global epidemic. HTLV-1 is associated with a wide spectrum of manifestations
including tropical spastic paraparesis, a disease characterized by the slow and
progressive development of myelopathy, as well as leukemia/lymphoma in adult
T-cells<sup><xref rid="B06" ref-type="bibr">6</xref></sup>. HTLV-1 is
endemic in many regions of the world, more common in adult women, and usually
insidious, but may be sudden. There is a high prevalence of HTLV-1 in southern
Japan, the Caribbean, Africa, South America, Papua New Guinea, the Middle East,
Australia, and Southeast Italy<sup><xref rid="B11" ref-type="bibr">11</xref></sup>.
In Brazil, HTLV-1 is found in several states, but is more prevalent in certain
regions, such as in the Northeast, particularly Maranh&#xE3;o, where the prevalence
is 10 per 1000 blood donors<sup><xref rid="B03" ref-type="bibr">3</xref></sup>.</p>
      <p id="para4">HTLV-1-associated myelopathy/tropical spastic paraparesis
(HAM/TSP) is a demyelinating disease with inflammatory changes in the
central nervous system. HTLV-1 is predominantly transmitted via blood; however,
vertical and sexual transmission is also possible<sup><xref rid="B12" ref-type="bibr">12</xref></sup>. HAM/TSP is characterized by neurological
manifestations, such as chronic spastic paraparesis, impaired gait, and weakness in
the lower limbs. Other symptoms include sphincter signs and symptoms such as bladder
disorders (urinary urge incontinence and nocturia) and sensory symptoms
including paresthesia, hyperreflexia of the lower limbs, and the presence of the
Babinski signal often with clonus (signs of pyramidal release). Laboratory
diagnosis is made by the identification of HTLV-1/2 antibodies in the blood and
cerebrospinal fluid (CSF). Results are confirmed by Western blot or
detection of proviral DNA in the blood or CSF<sup><xref rid="B12" ref-type="bibr">12</xref></sup>.</p>
      <p id="para5">In this study, a patient with HAM/TSP treated with interferon beta-1a
was presented, with a good outcome.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p id="para6">A 21-year-old widowed female patient, with a history of infective
dermatitis in childhood reported, decreased muscle strength in the upper and lower
limbs, particularly on the right side. The patient was seen as a referral to the
rehabilitation department. She was diagnosed with HTLV-1-associated
myelopathy/tropical spastic paraparesis, confirmed by positive levels of HTLV
in serum (ELISA: 3.15, Cut-Off: 0.18) and the CSF (ELISA: 2.57,
Cut-Off: 0.18). Additionally, anti-HTLV confirmation was made using Western
blot analyses.</p>
      <p id="para7">The referral hospital also identified antibodies in the CSF and excluded
mumps, cytomegalovirus, Epstein-Barr virus, schistosomiasis, herpes virus 1 and 2,
rubella, measles, toxoplasmosis, and varicella-zoster virus. Serology for hepatitis,
syphilis and HIV were also negative. Protein electrophoresis showed albumin values
of 15.6 mg/dL (normal range: 5.6-45.6 mg/dL), beta-globulin
values of 5.7 mg/dL (normal range: 0.8-10.8 mg/dL), and
gamma-globulin values of 7.2 mg/dL (normal range: 0.3-7.2
mg/dL). The complete blood count (CBC) was 3.09 million red
blood cells (RBCs)/mm<sup>3</sup>, 9.4 g/dL hemoglobin,
hematocrit 29%, lymphocytes 41%, erythrocyte sedimentation rate
(ESR) of 40 mm in the first hour, and 192,000 platelets.</p>
      <p id="para8">A differential diagnosis for demyelinating disease and lupus was
performed. Lupus and demyelinating disease were ruled out by clinical presentation
and laboratory tests for lupus (anticoagulant, anticardiolipin IgG and IgM, and
anti-DNA antibodies, all negatives). The serology of the patient's mother
could not be assessed, because she refused testing. The patient's husband was
also not tested, because he died before the onset of her clinical manifestations.
However, the patient has a daughter (aged two years) who was seropositive
for HTLV-1.</p>
      <p id="para9">One year prior to diagnosis of HTLV-1, the patient was diagnosed with
neurogenic bladder, with clinical nocturia (four times per night), urinary
urgency, severe loss of muscle strength in the lower limbs, positive Babinski reflex
and paresthesia in the left leg. The patient had also started walking with support
on the right side. The patient could walk 10 m in 12 s.</p>
      <p id="para10">Interferon beta-1a treatment (3,000,000 IU) was started three
times a week for 10 weeks. Clinical evaluations were performed after four weeks of
therapy. Improvement was first observed in sensory manifestations followed by motor
evaluation. The patient showed improvements in muscle strength and nocturia
(reduced to once per night) with the disappearance of urinary urgency and
paresthesia. The patient's gait became more agile and quick, and she could walk
10 m in 10 s. Two years after completing treatment, the patient still reports
improved clinical sensory and motor skills.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p id="para11">HTLV-1/2 infection is endemic in Brazil<sup><xref rid="B04" ref-type="bibr">4</xref></sup> where 5% of people are seropositive. There is
a high incidence in Maranh&#xE3;o, where 10 per 1000 blood donors are
seropositive<sup><xref rid="B03" ref-type="bibr">3</xref></sup>.
HTLV-1/2 is more frequent among women<sup><xref rid="B10" ref-type="bibr">10</xref></sup> in the fourth and fifth decade of life<sup><xref rid="B05" ref-type="bibr">5</xref></sup>, contrary to the age of the patient
in this study and the data provided by CARVALHO <italic>et al.</italic>
(2009)<sup><xref rid="B02" ref-type="bibr">2</xref></sup>.</p>
      <p id="para12">Several promising therapies have been considered and evaluated for
HAM/TSP, although none have been approved for use in patients yet.</p>
      <p id="para13">The treatment of HTLV-1-associated myelopathy/tropical spastic
paraparesis can be divided into specific and symptomatic cases. Specific
immunosuppressive drugs (corticosteroids) and/or immunomodulators
(interferon alpha and beta-1) are used for treatment. These drugs work to
inhibit T-lymphocyte activation, which modulates leukocyte migration and minimizes
the production of inflammatory cytokines. There are drugs for symptomatic treatment
that can control pain, neurogenic bladder, constipation, and spasticity<sup><xref rid="B01" ref-type="bibr">1</xref></sup>.</p>
      <p id="para14">Studies using interferon alpha to treat patients with HAM/TSP have
shown better clinical outcomes and reduced proviral loads<sup><xref rid="B08" ref-type="bibr">8</xref>,<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B16" ref-type="bibr">16</xref></sup>.</p>
      <p id="para15">Interferon beta-1a has been used to treat relapsing-remitting multiple
sclerosis and has been shown to be beneficial in several trials<sup><xref rid="B07" ref-type="bibr">7</xref>,<xref rid="B10" ref-type="bibr">10</xref></sup>. In HAM/TSP, only two studies evaluated interferon beta-1a
treatment. One study used a dose of 60 mcg twice per week, which reduced
tax-CD8+ cells, but did not reduce the proviral DNA load<sup><xref rid="B09" ref-type="bibr">9</xref></sup>. The other study used a lower dose
of 30 mcg every 15 days and noted good outcomes<sup><xref rid="B04" ref-type="bibr">4</xref></sup>.</p>
      <p id="para16">In this study, it was chosen to treat with interferon beta-1a instead of
interferon alpha, because the latter has a daily dosage schedule rather than the
simple weekly interferon beta-1a dosage.</p>
      <p id="para17">Treatment with interferon beta-1a (3,000,000 IU) three times a
week for 10 weeks improved the urinary and motor symptoms of the patient. Although
interferon beta-1a may not be the standard treatment for HTLV-1-associated
myelopathy/tropical spastic paraparesis, in this case it proved to be very
promising. This underscores the need for more clinical studies using interferon
beta-1a.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Ara&#xFA;jo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>MTT</given-names>
            </name>
          </person-group>
          <article-title>Avan&#xE7;os e perspectivas na terap&#xEA;utica das
doen&#xE7;as associadas &#xE0; infec&#xE7;&#xE3;o por HTLV</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Proietti</surname>
              <given-names>ABFC</given-names>
            </name>
          </person-group>
          <source>Cadernos Hemominas HTLV</source>
          <edition>4a ed</edition>
          <publisher-loc>Belo Horizonte</publisher-loc>
          <publisher-name>Funda&#xE7;&#xE3;o Hemominas</publisher-name>
          <year>2006</year>
          <fpage>228</fpage>
          <lpage>35</lpage>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho</surname>
              <given-names>AGJ</given-names>
            </name>
            <name>
              <surname>Galv&#xE3;o-Phileto</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Jesus</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Galv&#xE3;o-Castro</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>MGL</given-names>
            </name>
          </person-group>
          <article-title>Frequency of mental disturbances in HTLV-1 patients
in the state of Bahia, Brazil</article-title>
          <source>Braz J Infect Dis</source>
          <year>2009</year>
          <volume>13</volume>
          <fpage>5</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">19578622</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Catalan-Soares</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Carneiro-Proietti</surname>
              <given-names>ABF</given-names>
            </name>
            <name>
              <surname>Proetti</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Interdisciplinary HTLV Research</surname>
              <given-names>Group</given-names>
            </name>
          </person-group>
          <article-title>Heterogeneous geographic distribution of human
T-cell lymphotropic viruses I and II (HTLV I/II): serological
screening prevalence rates in blood donors from large urban areas in
Brazil</article-title>
          <source>Cad Sa&#xFA;de P&#xFA;blica</source>
          <year>2005</year>
          <volume>21</volume>
          <fpage>926</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">15868051</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costa</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Sundberg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Passos</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Muniz</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Interferon beta-1a improves urinary symptoms,
reduces proviral load, and modifies the immune response in a patient with
HAM/TSP. Case Rep Neurol Med</article-title>
          <source>2012</source>
          <year>2012</year>
          <fpage>1</fpage>
          <lpage>3</lpage>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaspar-Sobrinho</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>Souza-Machado</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Orge</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lessa</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>AA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical and immunological features of patients
with atopy and concomitant HLTV-1 infection</article-title>
          <source>Braz J Med Biol Res</source>
          <year>2010</year>
          <volume>43</volume>
          <fpage>1167</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">21140101</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gon&#xE7;alves</surname>
              <given-names>CCA</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>LCP</given-names>
            </name>
            <name>
              <surname>S&#xE1;</surname>
              <given-names>CAM</given-names>
            </name>
            <name>
              <surname>Puccioni-Sohler</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Diagn&#xF3;stico laboratorial da mielopatia
associada ao HTLV-I: m&#xE9;todos para an&#xE1;lise do l&#xED;quido
cefalorraquidiano</article-title>
          <source>J Bras Patol Med Lab</source>
          <year>2009</year>
          <volume>45</volume>
          <fpage>99</fpage>
          <lpage>110</lpage>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobs</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Cookfair</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Rudick</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Herndon</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Richert</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Salazar</surname>
              <given-names>AM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intramuscular interferon beta-1a for disease
progression in relapsing multiple sclerosis. The Multiple Sclerosis
Collaborative Research Group (MSCRG)</article-title>
          <source>Ann Neurol</source>
          <year>1996</year>
          <volume>39</volume>
          <fpage>285</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="pmid">8602746</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuroda</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kurohara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fujiyama</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Takashima</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Endo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Matsui</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Systemic interferon-alpha in the treatment of
HTLV-I-associated myelopathy</article-title>
          <source>Acta Neurol Scand</source>
          <year>1992</year>
          <volume>86</volume>
          <fpage>82</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">1519481</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oh</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Yamano</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mora</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Ohayon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bagnato</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Butman</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interferon-&#x3B2;1 a therapy in human
T-lymphotropic virus type I-associated neurologic disease</article-title>
          <source>Ann Neurol</source>
          <year>2005</year>
          <volume>57</volume>
          <fpage>526</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="pmid">15786444</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Randomised double-blind placebo-controlled study of interferon
beta-1a in relapsing/remitting multiple</surname>
              <given-names>sclerosis</given-names>
            </name>
          </person-group>
          <article-title>PRISMS (Prevention of Relapses and Disability
by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study
Group</article-title>
          <source>Lancet</source>
          <year>1998</year>
          <volume>352</volume>
          <issue>(9139)</issue>
          <fpage>1498</fpage>
          <lpage>504</lpage>
          <pub-id pub-id-type="pmid">9820297</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>R&#xEA;go</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Feitosa</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cavalcante</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Paran&#xE1;</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>VHC e HTLV-I: aspectos cl&#xED;nicos e
epidemiol&#xF3;gicos da co-infec&#xE7;&#xE3;o</article-title>
          <source>Rev Cienc M&#xE9;d Biol (Salvador)</source>
          <year>2003</year>
          <volume>2</volume>
          <fpage>230</fpage>
          <lpage>9</lpage>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ribas</surname>
              <given-names>JGR</given-names>
            </name>
            <name>
              <surname>Melo</surname>
              <given-names>GCN</given-names>
            </name>
          </person-group>
          <article-title>Mielopatia associada ao v&#xED;rus
linfotr&#xF3;pico humano de c&#xE9;lulas T do tipo 1
(HTLV-1)</article-title>
          <source>Rev Soc Bras Med Trop</source>
          <year>2002</year>
          <volume>35</volume>
          <fpage>377</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="pmid">12170334</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saito</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakagawa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kaseda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matsuzaki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jonosono</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eiraku</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Decreased human T lymphotropic virus type I
(HTLV-I) provirus load and alteration in T cell phenotype after
interferon-alpha therapy for HTLV-I associated myelopathy/tropical
spastic paraparesis</article-title>
          <source>J Infect Dis</source>
          <year>2004</year>
          <volume>189</volume>
          <fpage>29</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">14702150</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>FLN</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>FWM</given-names>
            </name>
          </person-group>
          <article-title>Epidemiologia, fisiopatogenia e diagn&#xF3;stico
laboratorial da infec&#xE7;&#xE3;o pelo HTLV-I</article-title>
          <source>J Bras Patol Med Lab</source>
          <year>2005</year>
          <volume>41</volume>
          <fpage>105</fpage>
          <lpage>16</lpage>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>NSO</given-names>
            </name>
            <name>
              <surname>Wigg</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>DP</given-names>
            </name>
          </person-group>
          <article-title>Viroses multissist&#xEA;micas</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Santos</surname>
              <given-names>NSO</given-names>
            </name>
            <name>
              <surname>Romanos</surname>
              <given-names>MTV</given-names>
            </name>
            <name>
              <surname>Wigg</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <source>Introdu&#xE7;&#xE3;o &#xE0; virologia humana</source>
          <edition> 2 ed</edition>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>Guanabara Koogan</publisher-name>
          <year>2008</year>
          <fpage>290</fpage>
          <lpage>330</lpage>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamasaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kira</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Koyanagi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kawano</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Miyano-Kurosaki</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Long term, high dose interferon-alpha treatment in
HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined
clinical, virological and immunological study</article-title>
          <source>J Neurol Sci</source>
          <year>1997</year>
          <volume>147</volume>
          <fpage>135</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">9106118</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
